SPS
CATX icon

Susquehanna Portfolio Strategies’s Perspective Therapeutics CATX Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$52.2K Buy
+12,528
New +$52.9K ﹤0.01% 949

Other funds holding CATX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna Portfolio Strategies's CATX Position: Q1 2026 in Review

Susquehanna Portfolio Strategies opened a new position in Perspective Therapeutics (CATX) in Q1 2026: 12,528 shares worth $52.2K. The stake represents ﹤0.01% of the portfolio and ranks #949 among its holdings.

138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • Susquehanna Portfolio Strategies held 12,528 shares of Perspective Therapeutics worth $52.2K as of Q1 2026.
  • Perspective Therapeutics was a new Susquehanna Portfolio Strategies position in Q1 2026.
  • Perspective Therapeutics made up ﹤0.01% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #949 holding.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.